Novel candidate live oral vaccines based on a Salmonella enterica serovar Typhi ZH9 (Ty2 ⌬aroC ⌬ssaV) derivative that directed the expression of either the B subunit of Escherichia coli heat-labile toxin or hepatitis B virus core antigen from the bacterial chromosome using the in vivo inducible ssaG promoter were constructed. The levels of attenuation of the two S. enterica serovar Typhi ZH9 derivatives were similar to that of the parent as assessed by measuring the replication of bacteria within human macrophage-like U937 cells. The expression of heterologous antigen in the respective S. enterica serovar Typhi ZH9 derivatives was up-regulated significantly within U937 cells compared to similar S. enterica serovar Typhi ZH9 derivative bacteria grown in modified Luria-Bertani broth supplemented with aromatic amino acids. Immunization of mice with these S. enterica serovar Typhi ZH9 derivatives stimulated potent antigen-specific serum immunoglobulin G responses to the heterologous antigens.
Live oral vaccines based on attenuated Salmonella enterica serovar Typhi derivatives are able to stimulate humoral, cellular, and local mucosal responses in vaccinees, making them attractive vehicles for delivering heterologous antigens (17) . The efficiency of this approach is likely to be dependent on the ability of the immunizing bacteria to optimally present heterologous (non-Salmonella) antigen to the human immune system. Unfortunately, synthesis of heterologous antigens in live vaccine vectors can place an additional metabolic burden on the vector, reducing "fitness" and thereby impacting upon the ability to stimulate an immune response (9) . This problem is compounded when the heterologous antigen is expressed using plasmid-based systems, as the metabolic burden can favor the selection of vector bacteria that have lost the plasmid encoding the heterologous gene (9) . Furthermore, the requirement for antibiotic resistance markers with traditional plasmid-based expression systems raises significant issues associated with the registration of any vaccine based on these derivatives.
There are a number of approaches to reducing the metabolic burden or stabilizing the plasmid loss associated with heterologous antigen expression. One approach relies on inactivating an essential gene, for example, that encoding aspartate ␤-semialdehyde dehydrogenase (asd), in the vector chromosome and inserting a copy of the same gene into the expression plasmid, the so-called balanced-lethal approach (8) . Another approach involves the exploitation of promoters (6) that activate heterologous antigen expression in vivo, thereby reducing the metabolic burden on the vector during vaccine production and the early phases of host colonization (2) . A further strategy involves integrating the heterologous gene into the vector chromosome. A limitation of chromosomal integration is that only a single copy of the heterologous gene is available to drive antigen expression (1, 7, 16) .
One approach for circumventing this limitation has been to combine chromosomal integration with the use of in vivo inducible promoters. Studies comparing the immune responses generated in mice following oral and intraperitoneal immunization with Salmonella strains expressing a PagC-alkaline phosphatase fusion protein from the chromosome under the control of either the in vivo inducible pagC promoter or a constitutive promoter have shown that only the strain utilizing the in vivo inducible promoter stimulated detectable immune responses against the heterologous PagC-alkaline phosphatase fusion protein (11) .
A live attenuated serovar Typhi-based oral typhoid vaccine strain, called serovar Typhi ZH9 (Ty2 ⌬aroC ⌬ssaV), was previously described (10) . Serovar Typhi ZH9 harbors independently attenuating deletion mutations in the aroC and ssaV genes. The aroC gene encodes chorismate synthase, an enzyme involved in the biosynthesis of aromatic compounds. Serovar Typhi aro derivatives are attenuated but can cause bacteremia in humans (12) . The ssaV gene encodes a component of the type III secretion system encoded on Salmonella pathogenicity island 2 (SPI-2). SPI-2 is required for S. enterica survival and growth within macrophages and, unlike serovar Typhi aro derivatives, serovar Typhi ZH9 does not cause bacteremia in humans (10) .
The aim of this study was to evaluate a combination of chromosomal integration and the SPI-2-associated in vivo in-ducible ssaG promoter as a basis for heterologous antigen expression and delivery in serovar Typhi ZH9 using the clinically relevant model antigens hepatitis B virus (HBV) core antigen (HBcAg) and the B subunit of Escherichia coli heatlabile toxin (LT-B). The ssaG promoter was selected because it has been shown previously to be up-regulated at least 400-fold in macrophages (18) .
MATERIALS AND METHODS
Bacterial strains, plasmids, media, and growth conditions. Bacteria were routinely grown at 37°C with shaking in modified Luria-Bertani broth (tryptone was replaced with soy peptone and supplemented with aromatic amino acids [mod LB aro]) or on agar (Difco, Detroit, Mich.) plates. The media were supplemented with ampicillin (100 mg/ml), kanamycin (50 mg/ml), aromatic compounds, and tyrosine (aromix) as required.
Construction of Salmonella derivatives. (i) Construction of serovar Typhi DTY8 and serovar Typhi ZH9. A human serovar Typhi strain, Ty2, isolated in 1916 from a patient with typhoid fever, was used as the background to create serovar Typhi DTY8 (Ty2 ⌬aroC) and serovar Typhi ZH9; their construction has been described previously (10, 13) .
(ii) Construction of control strains expressing LT-B or HBcAg from multicopy plasmids. Serovar Typhi ZH9 was transformed with either the plasmid pBRDO26 expressing LT-B from the constitutive tac promoter or the plasmid pPN1 expressing HBcAg from the constitutive tac promoter, using standard protocols as described previously (13) , to generate the strains ZH9/tac/eltB and ZH9/tac/HBcAg, respectively. The plasmids were maintained by growth in the presence of 100 g of ampicillin/ml. Expression of LT-B or HBcAg by the recombinant Salmonella strains was confirmed by capture enzyme-linked immunosorbent assay (ELISA) (see below).
(iii) Construction of serovar Typhi RSC5 (Ty2 ⌬aroC ⌬ssaV ssaG-HBcAg). (a) Modification of the T-cell epitope sequences in HBcAg and codon optimization for expression in serovar Typhi. The amino acid and nucleotide sequences of HBcAg from a clinical HBV isolate were kindly provided by Peter Karayiannis, Imperial College, London, United Kingdom. This sequence was subsequently modified to maximize the number of human T-cell epitopes encoded that conformed to previously identified T-cell epitope consensus sequences (3, 14) , although all of the CD4 ϩ and CD8 ϩ epitopes relevant to BALB/C (H-2 d ) mice were preserved. To improve expression of HBcAg in serovar Typhi, codon usage in the gene was modified to replace potentially poorly translated codons. Codons for modification were identified by comparing the average codon usage in the serovar Typhi genome to the codon usage in the highly expressed flagellin and heat shock protein genes. The modified HBcAg nucleotide sequence was then synthesized by Entelechon (Regensburg, Germany).
(b) Cloning of the ssaG-HBcAg fusion within an aroC deletion into the suicide vector pCVD442. The 0.47-kb ssaG promoter sequence was amplified from the chromosomal DNA of Salmonella enterica serovar Typhimurium TML by PCR and cloned into an intermediate vector along with the codon-optimized sequence encoding HBcAg to form a promoter-antigen fusion using standard techniques. The ssaG-HBcAg fusion was subsequently cloned into a modified version of pMIAC23, which is a pUC18-based vector containing a 4.8-kb HindIII fragment derived from serovar Typhi Ty2, which carries a defined 0.6-kb deletion in the aroC gene, to form pMIAC23/ssaG-HBcAg. A 5.8-kb fragment containing the ssaG-HBcAg fusion within the aroC deletion was excised from pMIAC23/ssaGHBcAg and cloned into the suicide vector pCVD442 using standard techniques to form pCVD442/ssaG-HBcAg.
(c) Insertion of the ssaG-HBcAg fusion into the chromosome of serovar Typhi ZH9 to generate serovar Typhi RSC5. The ssaG-HBcAg fusion was introduced into the chromosome of serovar Typhi ZH9 at the site of the attenuating aroC deletion by homologous recombination, using a method described previously (10) . Briefly, the pCVD442/ssaG-HBcAg construct was introduced into serovar Typhi ZH9 by electroporation. Ampicillin-resistant transformants were selected and allowed to grow in the absence of ampicillin to allow for loss of the pCVD442 DNA sequences and one copy of the aroC gene, either the deleted copy or the deleted copy harboring the ssaG-HBcAg fusion. Strains that had undergone this second recombination event were identified as ampicillin-sensitive derivatives that were able to grow in the presence of 10% sucrose. The aroC gene harboring the ssaG-HBcAg fusion and the ssaV deletion mutation were confirmed by PCR, Southern blotting, and sequence analysis. Several positive clones were analyzed, which led to the identification of serovar Typhi RSC5.
(iv) Construction of serovar Typhi TSB7 (Ty2 ⌬aroC ⌬ssaV ssaG-eltB). (a) Cloning of the ssaG-eltB fusion within an aroC deletion into the suicide vector pCVD442. The E. coli eltB open reading frame, which encodes the LT-B subunit, and the 0.47-kb ssaG promoter sequence (see above) were amplified by PCR and cloned into an intermediate cloning vector using standard techniques to form a promoter-antigen fusion. The final step in the generation of pCVD442/ssaG-eltB was to insert the ssaG-eltB fusion into the mutated aroC gene of serovar Typhi cloned in a pCVD442-based suicide vector. This was achieved by using the previously generated vector pCVD442/ssaG-HBcAg (see above). The suicide construct pCVD442/ssaG-eltB was generated by simply replacing the ssaG-HBcAg insert in pCVD442/ssaG-HBcAg with the ssaG-eltB insert from the intermediate vector using standard techniques to form pCVD442/ssaG-eltB.
(b) Insertion of the ssaG-eltB fusion into the chromosome of serovar Typhi ZH9 to generate serovar Typhi TSB7. The ssaG-eltB fusion was introduced into the chromosome of serovar Typhi ZH9 at the site of the attenuating aroC deletion by transformation with the suicide vector construct pCVD442/ssaG-eltB using a method identical to that described above for the generation of serovar Typhi RSC5 using pCVD442/ssaG-HBcAg. One strain, called serovar Typhi TSB7, was selected for further study. The insertion of the ssaG-eltB into the aroC deletion of serovar Typhi ZH9 and the integrity of the ssaV deletion were confirmed by PCR, Southern blotting, and sequence analysis.
Macrophage assays. (i) Preparation of bacteria and U937 monolayers. The survival of the vaccine strains serovar Typhi TSB7 and serovar Typhi RSC5 within human macrophage-like U937 cells was compared with those of the recipient strain ZH9 and the single aro mutant DTY8. Salmonella organisms were grown to stationary phase in Luria broth containing 0.3 M NaCl. U937 cells, obtained from the European Cell and Culture Collection, were grown in RPMI 1640 medium (Sigma) supplemented with glutamine (Sigma) and 10% fetal calf serum (Sigma). The cells were incubated at 37°C in 5% CO 2 and air. Cells were seeded into 24-well tissue culture plates at a concentration of 2 ϫ 10 5 to 3 ϫ 10 5 /well and activated with 100 nM phorbol 12-myristate 13-acetate (Sigma). The cells became adherent once they had been activated. The cells were incubated for 4 to 5 days until a confluent monolayer was formed.
(ii) Intracellular replication assay. Stationary-phase bacteria were opsonized by adding an equal volume of human serum minus immunoglobulin A (IgA) (Sigma) at a concentration of 50 mg/ml. The mixture was subsequently vortexed and incubated for 20 min at room temperature. The opsonized bacteria were added to each well at a multiplicity of infection of 50:1. Each strain was tested in triplicate. After incubation at 37°C and 5% CO 2 for 30 min, the medium was removed from the infected monolayers and replaced with complete medium containing 200 g of gentamicin (Gibco-BRL)/ml so that any remaining extracellular bacteria were killed. After a further 1-h incubation, this medium was replaced with complete medium containing 16 g of gentamicin/ml for the remainder of the incubation period. At different time points following infection, the infected U937 monolayers were washed three times with phosphate-buffered saline (PBS; Gibco-BRL). The salmonellae were harvested by lysing the macrophages with PBS plus 1% Triton X-100 for 20 min. The lysates were collected and serially diluted in maximal recovery diluent (0.85% NaCl and 0.1% soy peptone), and aliquots were spread on brain heart infusion plus aromatic amino acid mixture plates to assess viability.
(iii) Intracellular expression. To induce expression of the heterologous antigen, U937 cells were grown in 75-cm 3 tissue culture flasks as described above. Similar to the replication assay, the cells were washed with complete medium prior to bacterial invasion. Stationary-phase Salmonella organisms were opsonized, and the bacteria were added to each flask at a multiplicity of infection of ϳ50:1. The flasks were incubated for 60 min at 37°C and 5% CO 2 . Extracellular bacteria were removed by the addition of complete medium containing 200 g of gentamicin/ml. After a further incubation of 60 min, the medium was replaced with complete medium containing 16 g of gentamicin/ml, and the flasks were incubated at 37°C and 5% CO 2 for 24 h. After this period, the cells were washed repeatedly with PBS and lysed with PBS plus 1% Triton X-100 for 20 min to release the salmonellae. The bacteria were harvested by centrifugation, resuspended in PBS, and split into aliquots of equal volume. One aliquot was resuspended in B-PER lysis buffer (Pierce), and the levels of expression in these lysates were quantified by ELISA as outlined below. The other aliquot was serially diluted in maximal recovery diluent, and aliquots were spread on brain heart infusion plus aromatic amino acid mixture plates to assess viability.
Quantification of heterologous antigen expression. (i) Quantification of LT-B expression.
To quantify the levels of LT-B produced by serovar Typhi TSB7, a GM1 capture ELISA was employed as outlined previously (13) . Briefly, flatbottom 96-well Immulon-4 plates (Dynex) were coated overnight at 4°C with 1.5 g of GM1 gangliosides (Sigma)/well, blocked for 1 h at 37°C with 3% bovine serum albumin (BSA) in PBS-0.05% Tween 20 (PBST), and then incubated with
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whole-cell lysates of Salmonella in PBST for 1 h at 37°C. A standard curve was created by serially diluting purified LT from 80 to 0.039 ng/ml in PBS-Tween. These dilutions were then added to the cell lysates, and the plate was incubated for 1 h at 37°C. Following extensive washing, the LT-B was detected by using a goat anti-LT polyclonal antibody (Biogenesis Ltd.), followed by biotinylated rabbit anti-goat (Dako, Oxford, United Kingdom) and streptavidin peroxidase (Dako) with o-phenylenediamine dihydrochloride (OPD) substrate (1 mg/ml). After 30 min at 37°C, the reaction was stopped by the addition of 30 l of 2 M H 2 SO 4 /well, and the absorbance was read at 492 nm using an automated Dynex MRX ELISA plate reader. The concentration of LT-B in a sample was read from the standard curve using the optical density at 492 nm (OD 492 ). The results were calculated using Revelation software (Dynex). The concentrations of LT-B produced by attenuated Salmonella were expressed as nanograms of LT-B per 10 9 CFU of Salmonella.
(ii) Quantification of HBcAg expression. To quantify the levels of HBcAg produced by serovar Typhi RSC5, a capture ELISA was developed. Flat-bottom 96-well Immulon-4 plates were coated overnight at 4°C with 50 l of an antihepatitis B core antigen monoclonal antibody (Europa Bioproducts)/well diluted 1 in 1,000 in PBS (Sigma). The plates were washed in PBST and then blocked for 1 h at 37°C with 200 l of 3% BSA per well in PBS-0.05% Tween 20 solution. The plates were subsequently rewashed and then incubated for 60 min with whole-cell lysates of Salmonella resuspended in PBST and shaken at 37°C. A standard curve was created by serially diluting purified HBcAg (Aalto Bio Reagents Ltd.) in PBST, generating a concentration range between 20 and 0.5 ng/ml. Following extensive washing, 50 l of a rabbit anti-HBcAg polyclonal antibody (Europa Bioproducts Ltd)/well diluted 1 in 2,000 in PBST plus 1% BSA was added to each well, and the plates were incubated for 1 h at 37°C with constant shaking. The plates were then washed in PBST before the addition of 50 l of a goat anti-rabbit IgG horseradish peroxidase (HRP)-conjugated antibody (Cambridge Bioscience Ltd.)/well diluted 1 in 8,000 in PBST plus 1% BSA. Following washing, bound HBcAg was detected by the addition of OPD substrate (1 mg/ml; Sigma). After 15 min at 37°C, the reaction was stopped by the addition of 30 l of 2 M H 2 SO 4 /well, and the absorbance was read at 492 nm using an automated Dynex MRX ELISA plate reader. The concentration of HBcAg in a sample was read from the standard curve using the OD 492 value. The results were calculated using Revelation software. The concentrations of HBcAg produced by attenuated Salmonella were expressed as nanograms of HBcAg per 10 9 CFU of Salmonella. Mice. Female BALB/c (H-2 d ) mice aged 6 to 8 weeks were obtained from Harlan-Olac, Bicester, United Kingdom, and housed at the Central Biological Services at the Imperial College of Science, Technology and Medicine, London, United Kingdom. All procedures were performed according to the Home Office guidelines for animals in medical research.
Immunization of mice. Mice were immunized either intranasally or subcutaneously. The mice were anesthetized with halothane prior to intranasal inoculation. The anesthetized mice were inoculated with a total volume of 20 l of a 5 ϫ 10 10 CFU per ml bacterial suspension (10 9 CFU per mouse) into the left and right nares (10 l/nare; 20 l total), using a Finn pipette, by placing a droplet onto the nasal passage and allowing the mouse to breathe in the inoculum before adding additional droplets. The mice were immunized subcutaneously at the base of the tail and the back of the neck with a total volume of 100 l of a 5 ϫ 10 8 CFU per ml bacterial suspension (5 ϫ 10 7 CFU per mouse), using a 25-gauge needle (Plastipak, Madrid, Spain) and a 1-ml syringe (Kendall, United Kingdom). The mice were observed until they were fully recovered. Blood was collected by tail bleeding. The sera were obtained by centrifugation of blood over Seraseive and stored at Ϫ80°C. Antibody measurements. (i) ELISA for the detection of anti-LT specific serum IgG. Flat-bottom 96-well Immulon-4 plates were coated with 50 l of a 30-g/ml solution of GM1 (Sigma)/well (1.5 l/well) diluted in 50 mM carbonate buffer, pH 9.6, and incubated overnight at 4°C. After six washes with PBST, the plates were blocked with 100 l of PBST plus 3% BSA/well and incubated for 1 h at 37°C with constant shaking. The plates were then rewashed as described above. Purified LT (50 l/well; Sigma) at a concentration of 1 g/ml (diluted in PBST) was added, and the plates were incubated for 1 h at 37°C with constant shaking. The plates were then rewashed as described above. Each well was subsequently incubated with 50 l of diluted experimental mouse serum (diluted in PBST) for 1 h at 37°C with constant shaking. Control wells containing preimmune sera and sera from mice immunized subcutaneously with purified LT (Sigma) were set up as a negative and positive control, respectively. The dilution range of experimental sera ranged from 1:50 to Ͼ1:100,000. Inclusion of the same positive control sera on each plate allowed direct comparison of assays carried out on different days. Following a further six washes, bound serum IgG was detected by the addition of 50 l of a 1:1 mixture of HRP-conjugated goat anti-mouse IgG1 and IgG2a/well, each diluted 1:4,000 in PBST (Southern Biotechnologies Inc.). The plates were washed as outlined above, and bound IgG was detected by the addition of 100 l of OPD substrate/well (1 mg/ml; made using Sigmafast OPD two-tablet sets; Sigma). After 15 min at 37°C, the reaction was stopped by the addition of 30 l of 2 M H 2 SO 4 /well, and the absorbance was read at 492 nm using an automated Dynex MRX ELISA plate reader. The absorbance values were expressed as end point titers, which was the last dilution of sample at which the OD 492 was greater than or equal to twice the mean OD 492 of the control prebleed wells.
(ii) ELISA for detection the of anti-HBcAg-specific serum IgG. Flat-bottom 96-well Immulon-4 plates were coated with 50 l of a 1-g/ml solution of recombinant purified HBcAg (Aalto Bioreagents)/well diluted in 50 mM carbonate buffer, pH 9.6, and incubated overnight at 4°C. After six washes with PBST, the plates were blocked with 100 l of PBST plus 3% BSA/well and incubated for 1 h at 37°C with constant shaking. The plates were then rewashed as described above. Each well was subsequently incubated with 100 l of diluted experimental mouse serum (diluted in PBST) for 1 h at 37°C with constant shaking. Control wells containing preimmune sera and sera from mice immunized subcutaneously with purified HBcAg and Ribi adjuvant (Corixa Corp., Seattle, Wash.) were set up as negative and positive controls, respectively. The dilution range of experimental sera ranged from 1:100 to Ͼ1:100,000. Inclusion of the same positive control sera on each plate allowed direct comparison of assays carried out on different days. Following a further six washes, bound serum IgG was detected by the addition of 50 l of a 1:1 mixture of HRP-conjugated goat anti-mouse IgG1 and IgG2a/well, each diluted 1:4,000 in PBST (Southern Biotechnologies Inc.). Specific IgG1 or IgG2a responses were measured by using the respective conjugates separately. The plates were washed as outlined above, and bound IgG was detected by the addition of 100 ll of OPD substrate/well (1 mg/ml; made using Sigmafast OPD two-tablet sets). After 15 min at 37°C, the reaction was stopped by the addition of 30 l of 2 M H 2 SO 4 /well, and the absorbance was read at 492 nm using an automated Dynex MRX ELISA plate reader. The absorbance values were expressed as end point titers as defined above.
Statistical method. Statistical significance was calculated using a two-sample t test assuming equal variance between populations with a confidence level of 95% (P ϭ Ͻ0.05).
RESULTS

Survival of different serovar Typhi vaccine derivatives in
human macrophage-like U937 cells. The levels of replication of different candidate serovar Typhi vaccine derivatives within human macrophage-like U937 cells have been shown to correlate with their degrees of attenuation in humans (4, 5) . Therefore, a reduction in replication of serovar Typhi TSB7 and serovar Typhi RSC5 in human macrophages would be strong evidence supporting the safety of these strains in humans. Replication of the vaccine candidates serovar Typhi TSB7 and serovar Typhi RSC5 was compared with replication of the parent strain, serovar Typhi ZH9, and a Ty2 ⌬aroC derivative, serovar Typhi DTY8. The bacteria were opsonized and added to the activated U937 cells, and uptake was allowed to occur for 30 min, after which any extracellular bacteria were killed by the addition of gentamicin. Macrophages were lysed, and the numbers of bacteria were determined at 2 and 48 h so that the amount of bacterial replication or killing could be assessed. The results are shown in Fig. 1 . There was no significant difference among the survival rates of serovar Typhi TSB7, serovar Typhi RSC5, and serovar Typhi ZH9 after 48 h, suggesting that the insertion of a promoter-antigen fusion into the chromosome did not affect the replication-deficient phenotype of the vaccine candidates in this system. In contrast, the single aro mutant serovar Typhi DTY8 demonstrated significantly higher levels of replication.
Up-regulation of heterologous antigen expression in human macrophage-like U937 cells. The expression of heterologous antigen in the serovar Typhi vaccine derivatives is directed by the in vivo up-regulated promoter ssaG. To induce expression of heterologous antigen in vitro, we infected a human macrophage-like U937 cell line with serovar Typhi TSB7, serovar Typhi RSC5, or serovar Typhi ZH9 (negative control) as described above, except that the bacteria were incubated for a 24-h period. The macrophages were subsequently lysed, the bacteria were isolated, and heterologous antigen expression was measured by ELISA. In addition, the viability of the bacteria was evaluated so that the amount of heterologous antigen synthesized could be expressed as a function of the number of viable bacteria. The results outlined in Fig. 2 show that both serovar Typhi TSB7 ( Fig. 2A) and serovar Typhi RSC5 (Fig.  2B) can direct the expression of heterologous antigen, demonstrating the functionality of the integrated ssaG-antigen fusions. Furthermore, a comparison of the level of heterologous antigen expression in U937 cells with that in the same derivatives grown overnight in mod LB aro broth demonstrated that the ssaG promoter up-regulates expression at least 500-fold in human macrophage-like U937 cells.
Serovar Typhi TSB7 elicits potent serum antibody responses in mice following subcutaneous inoculation. To evaluate the ability of serovar Typhi TSB7 to drive anti-LT responses in vivo, mice were immunized subcutaneously with a single dose of 5 ϫ 10 7 CFU. The subcutaneous route of administration was chosen because serovar Typhi has been shown to be poorly immunogenic in mice when delivered orally (15) . In addition, mice were immunized with the parent strain, serovar Typhi ZH9, and serovar Typhi ZH9 expressing LT-B from a multicopy plasmid under the control of a tac promoter (ZH9/tac/eltB) as negative and positive controls, respectively. ZH9/tac/eltB had been shown previously to elicit potent anti-LT responses in mice (13) . Blood was collected by tail bleeding on days 28 and 42, and anti-LT responses were measured by ELISA. Mice inoculated subcutaneously with ZH9/tac/eltB and serovar Typhi TSB7 exhibited potent LT-specific serum IgG responses on both days 28 and 42, as shown in Fig. 3 . There was no significant difference (P Ͼ 0.05) between the responses generated by the two vaccines on either day 28 or 42, demonstrating the utility of the serovar Typhi strain TSB7 as a vehicle for stimulating anti-LT responses in vivo. Interestingly, similar responses were observed when serovar Typhi TSB7 was administered intranasally (data not shown). RSC5 elicits potent serum antibody responses with a strong IgG2a bias in mice following nasal inoculation. To evaluate the ability of serovar Typhi RSC5 to drive anti-HBcAg responses in vivo, mice were immunized intranasally with a single dose of 10 9 CFU of serovar Typhi RSC5. In addition, mice were immunized with the parent strain, serovar Typhi ZH9, and serovar Typhi ZH9 expressing HBcAg from a multicopy plasmid under the control of a tac promoter (ZH9/tac/HBcAg) as negative and positive controls, respectively. Blood was collected by tail bleeding on days 28 and 70, and anti-HBcAg responses were measured by ELISA. Mice inoculated intranasally with ZH9/tac/HBcAg or serovar Typhi RSC5 exhibited high levels of serum HBcAg-specific IgG responses on both days 28 and 70, as shown in Fig. 4 . Low-level anti-HBcAg serum IgG responses were measured in a number of control mice inoculated intranasally with serovar Typhi ZH9. The mice from each of these treatment groups were kept in separate cages, and each mouse was individually tagged. It is therefore highly unlikely that these background responses were the result of cross-contamination, and the background responses probably represent nonspecific "noise" resulting from cross-reactivity between the anti-serovar Typhi lipopolysaccharide antibody raised in these mice and the E. coli lipopolysaccharide contamination present in the recombinant HBcAg used in the ELISA. However, the IgG responses measured in mice immunized with ZH9/tac/HBcAg and serovar Typhi RSC5 were significantly higher than the background responses measured in control mice immunized with serovar Typhi ZH9 (P Ͻ 0.05). There was no significant difference between the magnitudes of the anti-HBcAg antibody responses in mice immunized with either ZH9/tac/HBcAg or serovar Typhi RSC5 (P Ͼ 0.05) on day 28 or 70. Interestingly, although immunization with ZH9/tac/ HBcAg and serovar Typhi RSC5 stimulated similar levels of anti-HBcAg IgG2a in mice, the level of IgG1 was significantly lower (P ϭ 0.02) in animals immunized with serovar Typhi RSC5 on both days 28 and 70, as shown in Fig. 5 . This suggests that serovar Typhi RSC5 preferentially stimulates IgG2a production, indicative of a Th1-biased response against the heterologous antigen. Interestingly, similar responses were observed when serovar Typhi RSC5 was administered subcutaneously (data not shown). 
DISCUSSION
The ability of serovar Typhi to colonize important immunological niches and stimulate a diverse range of immune effecter mechanisms makes it an attractive vehicle for delivering heterologous antigens. However, issues regarding the stability of heterologous antigen expression and the use of antibiotic markers have limited the exploitation of Salmonella-based vaccines in the clinic. Here, we describe the construction of two recombinant vaccine candidates, serovar Typhi TSB7 and serovar Typhi RSC5, that express LT-B and HBcAg, respectively, in a stable fashion. This was achieved by integrating a single copy of the heterologous gene into the serovar Typhi chromosome associated with the in vivo inducible ssaG promoter. We have shown that these recombinant vaccines are genetically stable (data not shown) and that the insertion of the promoter-antigen fusion did not detectably influence the level of attenuation afforded by the aroC and ssaV mutations. No heterologous antigen was detected when serovar Typhi TSB7 and serovar Typhi RSC5 were grown overnight in mod LB aro broth. In contrast, both LT-B and HBcAg expression levels were significantly up-regulated when the same serovar Typhi derivatives were cultured for a 24-h period in U937 human macrophage-like cells, suggesting that antigen expression is significantly up-regulated in these cells, which is consistent with previous findings (18) . Therefore, it is reasonable to presume that expression of the heterologous antigen is minimal during fermentation, eliminating any metabolic burden during vaccine manufacture. In support of this hypothesis is the observation that both serovar Typhi TSB7 and serovar Typhi RSC5 demonstrate growth kinetics very similar to those of the recipient, serovar Typhi ZH9 (data not shown). Furthermore, insertion of the heterologous gene into the chromosome eliminates the requirement for antibiotics in the growth medium during production.
The ability of the ssaG promoter to drive immunologically relevant levels of heterologous antigen from a single chromosomally located copy of the heterologous gene was evaluated in vivo. Mice were inoculated either intranasally with 10 9 CFU or subcutaneously with 5 ϫ 10 7 CFU of serovar Typhi RSC5 and serovar Typhi TSB7, respectively, and the antigen-specific IgG responses were measured by ELISA. Both strains stimulated potent antibody responses, demonstrating the utility of the ssaG promoter in driving immunologically relevant levels of antigen. Interestingly, no response to the heterologous antigen was observed when the ssaG promoter was replaced with the constitutive promoter trc (data not shown), which is consistent with previous findings (11) . This probably reflects the ability of the ssaG promoter to direct high levels of antigen expression in a manner both temporally and physically ideal for generating an immune response. Analysis of the antigen-specific IgG isotypes demonstrated a predominance of IgG2a over IgG1 for both of the antigens, which is indicative of a Th1-biased response (although the bias against the LT-B antigen was not as marked [data not shown] as that observed for HBcAg), suggesting that the vector may be ideal for stimulating these types of responses. These studies outline the value of combining ssaG-driven antigen expression with chromosomal integration in the serovar Typhi ZH9 background as a strategy for developing clinically acceptable, stable, and highly immunogenic recombinant Salmonella-based vaccines. 
